Reata Pharmaceuticals Statistics

Share Statistics

Reata Pharmaceuticals has 38.1M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding Shares Outstanding n/a Close	38.1M
Shares Change (YoY) Shares Change (YoY) n/a Close	0%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	n/a
Shares Floating Shares Floating n/a Close	29.79M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	680
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.07%

Short Selling Information

The latest short interest is 2.39M, so 6.28% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	2.39M
Short % of Shares Out Short % of Shares Out n/a Close	6.28%
Short % of Float Short % of Float n/a Close	8.14%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	3.09

Valuation Ratios

The PE ratio is -4.42 and the forward PE ratio is null. Reata Pharmaceuticals's PEG ratio is -0.91.

PE Ratio PE Ratio n/a Close	-4.42
Forward PE Forward PE n/a Close	n/a
PS Ratio PS Ratio n/a Close	622.68
Forward PS Forward PS n/a Close	n/a
PB Ratio PB Ratio n/a Close	-21
P/FCF Ratio P/FCF Ratio n/a Close	-6.65
PEG Ratio PEG Ratio n/a Close	-0.91

Financial Ratio History

Enterprise Valuation

Reata Pharmaceuticals has an Enterprise Value (EV) of 1.46B.

EV / Sales EV / Sales n/a Close	657.49
EV / EBITDA EV / EBITDA n/a Close	-5.42
EV / EBIT EV / EBIT n/a Close	-7.13
EV / FCF EV / FCF n/a Close	-7.02

Financial Position

The company has a current ratio of 6.75, with a Debt / Equity ratio of -1.82.

Current Ratio Current Ratio n/a Close	6.75
Quick Ratio Quick Ratio n/a Close	6.75
Debt / Equity Debt / Equity n/a Close	-1.82
Debt / EBITDA Debt / EBITDA n/a Close	-0.44
Debt / FCF Debt / FCF n/a Close	-0.58
Interest Coverage Interest Coverage n/a Close	-6.47

Financial Efficiency

Return on Equity is 474.77% and Return on Invested Capital is -502.4%.

Return on Equity Return on Equity n/a Close	474.77%
Return on Assets Return on Assets n/a Close	-60.62%
Return on Invested Capital Return on Invested Capital n/a Close	-502.4%
Revenue Per Employee Revenue Per Employee n/a Close	$6,903.43
Profits Per Employee Profits Per Employee n/a Close	$-971,654.21
Employee Count Employee Count n/a Close	321
Asset Turnover Asset Turnover n/a Close	0
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	-25K
Effective Tax Rate Effective Tax Rate n/a Close	0.01%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 1.42, so Reata Pharmaceuticals's price volatility has been higher than the market average.

Beta Beta n/a Close	1.42
52-Week Price Change 52-Week Price Change n/a Close	n/a
50-Day Moving Average 50-Day Moving Average n/a Close	159.77
200-Day Moving Average 200-Day Moving Average n/a Close	95.71
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	84.69
Average Volume (20 Days) Average Volume (20 Days) n/a Close	954,093

Income Statement

In the last 12 months, Reata Pharmaceuticals had revenue of 2.22M and earned -311.9M in profits. Earnings per share was -8.59.

Revenue Revenue n/a Close	2.22M
Gross Profit Gross Profit n/a Close	2.22M
Operating Income Operating Income n/a Close	-270.15M
Net Income Net Income n/a Close	-311.9M
EBITDA EBITDA n/a Close	-269.02M
EBIT EBIT n/a Close	-270.15M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-8.59

Full Income Statement

Balance Sheet

The company has 42.31M in cash and 119.46M in debt, giving a net cash position of -77.15M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	42.31M
Total Debt Total Debt n/a Close	119.46M
Net Cash Net Cash n/a Close	-77.15M
Retained Earnings Retained Earnings n/a Close	-1.57B
Total Assets Total Assets n/a Close	502.59M
Working Capital Working Capital n/a Close	276.76M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -204.27M and capital expenditures -3.27M, giving a free cash flow of -207.54M.

Operating Cash Flow Operating Cash Flow n/a Close	-204.27M
Capital Expenditures Capital Expenditures n/a Close	-3.27M
Free Cash Flow Free Cash Flow n/a Close	-207.54M
FCF Per Share FCF Per Share n/a Close	-5.71

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -12191.11% and -14074.95%.

Gross Margin Gross Margin n/a Close	100%
Operating Margin Operating Margin n/a Close	-12191.11%
Pretax Margin Pretax Margin n/a Close	-14076.08%
Profit Margin Profit Margin n/a Close	-14074.95%
EBITDA Margin EBITDA Margin n/a Close	-12140.12%
EBIT Margin EBIT Margin n/a Close	-12191.11%
FCF Margin FCF Margin n/a Close	-9365.39%

Dividends & Yields

RETA does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	-22.6%
FCF Yield FCF Yield n/a Close	-15.04%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for RETA.

Price Target Price Target n/a Close	n/a
Price Target Difference Price Target Difference n/a Close	n/a
Analyst Consensus Analyst Consensus n/a Close	n/a
Analyst Count Analyst Count n/a Close	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Scores

Altman Z-Score Altman Z-Score n/a Close	5.36
Piotroski F-Score Piotroski F-Score n/a Close	2

Reata Pharmaceuticals Inc... (RETA)